Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | LOX | P28300 | 1/20 | 0.33 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.31 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.31 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4754035 | 1.00 | TSHR (0.43) | TSHRALDH1A1TDP1MAPTLOX | |
| SCHEMBL4754670 | 1.00 | TSHR (0.43) | TSHRALDH1A1TDP1MAPTLOX | |
| SCHEMBL4757205 | 1.00 | TSHR (0.43) | TSHRALDH1A1TDP1MAPTLOX | |
| SCHEMBL547962 | 1.00 | TSHR (0.43) | TSHRALDH1A1TDP1MAPTLOX | |
| SCHEMBL4756519 | 1.00 | TSHR (0.43) | TSHRALDH1A1TDP1MAPTLOX | |
| SCHEMBL7616059 | 1.00 | TSHR (0.43) | TSHRALDH1A1TDP1MAPTLOX | |
| SCHEMBL4754566 | 1.00 | TSHR (0.43) | TSHRALDH1A1TDP1MAPTLOX | |
| SCHEMBL4755738 | 1.00 | TSHR (0.43) | TSHRALDH1A1TDP1MAPTLOX | |
| SCHEMBL4757182 | 1.00 | TSHR (0.43) | TSHRALDH1A1TDP1MAPTLOX | |
| SCHEMBL1228368 | 1.00 | TSHR (0.43) | TSHRALDH1A1TDP1MAPTLOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10854881-B2 | Binder for lithium cell | TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) | 2020-12-01 | — | — | US | disclosed |
| CN-111253513-A | Use of a binder for lithium batteries in the manufacture of an electrode for lithium batteries comprising a silicon-containing active substance | 富士胶片和光纯药株式会社 | 2020-06-09 | — | — | CN | disclosed |
| CN-106233514-B | Binder for lithium battery | 富士胶片和光纯药株式会社 | 2020-04-21 | — | — | CN | disclosed |
| EP-3136483-B1 | BINDER FOR LITHIUM CELL | FUJIFILM WAKO PURE CHEMICAL CORP (JP) | 2018-08-01 | — | — | EP | disclosed |
| EP-3136483-A1 | BINDER FOR LITHIUM CELL | Wako Pure Chemical Industries, Ltd. (JP) | 2017-03-01 | — | — | EP | disclosed |
| US-20170040612-A1 | BINDER FOR LITHIUM CELL | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2017-02-09 | — | — | US | disclosed |
| WO-2008110612-A2 | NOVEL COMPOUNDS AND LUBRICATING COMPOSITIONS COMPRISING THE SAME | SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) | 2008-09-18 | — | — | WO | disclosed |
| EP-1084710-B1 | ADENOSINE A1 ANTAGONISTS FOR MALE STERILITY | ASTELLAS PHARMA INC (JP) | 2006-10-18 | — | — | EP | disclosed |
| US-20040152659-A1 | Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2004-08-05 | — | — | US | disclosed |
| US-6521656-B1 | Contacting sperm with a pyrazolo(1,5-a)pyridine acrosomal reaction induction promoter then joining with ovum | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-02-18 | — | — | US | disclosed |
| US-5643938-A | RAISING THE ERYTHROPOIETIN LEVEL IN HUMANS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-07-01 | — | — | US | disclosed |
| EP-0644762-A1 | PYRAZOLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF ANEMIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-03-29 | — | — | EP | disclosed |
| US-5338743-A | Pancreatitis | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-08-16 | — | — | US | disclosed |
| WO-1993025205-A1 | PYRAZOLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF ANEMIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-12-23 | — | — | WO | disclosed |
| US-5204346-A | Cognition activators; analgesics; antidepressants; vasodilation; cardiovascular and urogential disorders; | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-04-20 | — | — | US | disclosed |
| EP-0497258-A2 | Use of adenosine antagonists in the prevention and treatment of pancreatitis and ulcer | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-08-05 | — | — | EP | disclosed |
| US-5069991-A | NAPHTHOLACTAM OR ISINDOLENINE DYE | BASF AKTIENGESELLSCHAFT (DE) | 1991-12-03 | — | — | US | disclosed |
| EP-0364890-A2 | Panchromatic electrophotographical recording element | BASF Aktiengesellschaft (DE) | 1990-04-25 | — | — | EP | disclosed |
| US-4906541-A | Electrophotographic recording element containing a naphtholactam dye sensitizer | BASF AKTIENGESELLSCHAFT (DE) | 1990-03-06 | — | — | US | disclosed |
| EP-0318758-A2 | Multilayered electrophotographical recording material | BASF Aktiengesellschaft (DE) | 1989-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152659-A1 | Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist | ADORA2A, ADORA1, ADORA2B | TSHR 601/4885ALDH1A1 336/4885TDP1 1319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.